Remove 2005 Remove Immune Response Remove Licensing Remove Regulations
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy 86:151-183 (2005). Normality sensing licenses local T cells for innate-like tissue surveillance. Regulation of cutaneous malignancy by gammadelta T cells. References Fichtner A, Ravens S, Prinz I. Cells 9(40):800 (2020).

Therapies 103
article thumbnail

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

The Pharma Data

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2005; 172; 149–60. J Intern Med 2012;272:121–32.

Trials 52
article thumbnail

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma

The Pharma Data

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2005; 172: 149-160. 2019;12(5):539-549.

Trials 40